Artificial Intelligence May Discover the Next Blockbuster Drug
Ken Mulvaney, CEO of Benevolent AI, discusses the opportunities and challenges that come with applying machine learning to drug development.
AI is revolutionizing countless industries, but its biggest impact may be felt in medicine. Machine learning has proved capable of identifying signs of disease in medical images and records, and it may become invaluable for analyzing vast genomic data sets for clues as to the origins of different disorders. Benevolent AI, headquartered in London, is working to apply the latest AI techniques to the identification and development of novel drug compounds. The company’s CEO, Ken Mulvaney, met with MIT Technology Review’s senior editor for AI, Will Knight, to discuss AI’s relevance to drug discovery and medicine, and to talk about his company’s ambitious plans.
Recommended for You
About this series
This story is part of our ongoing Insider Conversations series that allows Premium subscribers to be a part of the conversation as our editors talk with innovators and entrepreneurs. See the whole series here.
If you are an Insider Premium subscriber, we'll send you an email announcing the next Insider Conversation. Keep an eye out and we hope you can join us.